Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus KYLEENA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus KYLEENA.
ANNOVERA vs KYLEENA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
Levonorgestrel is a progestin that suppresses endometrial proliferation, thickens cervical mucus, and induces endometrial atrophy. It also partially inhibits ovulation.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
KYLEENA (levonorgestrel-releasing intrauterine system 19.5 mg) is inserted into the uterine cavity by a healthcare professional. One system releases levonorgestrel at approximately 17.5 mcg/day initially, decreasing to 7.4 mcg/day after 1 year and 5.1 mcg/day after 3 years, and is effective for up to 5 years.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal elimination half-life is approximately 25 hours (range 18–30 hours) after repeated dosing; supports once-daily dosing but not applicable for IUD as systemic absorption is minimal.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal (fecal negligible). Levonorgestrel is extensively metabolized; metabolites are excreted primarily in urine (40–68%) and to a lesser extent in feces (16–48%).
Category C
Category C
Contraceptive
Contraceptive